tbuckley/cabot-search huggingface dataset:
PTU-066 Lipid Biomarker as a Diagnostic Tool in Crohn’s Disease Using Metabonomic Profiling in Serum and Faeces
Authors: NS Ding, M Sarafian, R Misra, PA Hendy, L Penez, E Holmes, AL Hart
Journal: Gut (2016)

<h3>Introduction</h3> Inflammatory bowel disease (IBD) is influenced by environmental and genetic factors which alters the gut microbiota. The human gut microbiota is involved in the maintenance of its host physiological functions and imbalance in the microbial population and its metabolic signatures may lead to disease activity and phenotype. We aimed to investigate the variations occurring in lipid metabolism between Crohn’s disease (CD) <i>vs</i>. controls in serum and faeces by profiling using a metabonomic approach. <h3>Methods</h3> Serum and faeces were collected from moderate to severe Crohn’s disease patients prior to commencement of anti- TNF. Sample preparation: Protein precipitation with isopropanol was implemented on serum and faeces samples and prepared by biphasic extraction.Lipid profiling: The method was performed on Waters Acquity UPLCTM combined with Waters Q-Tof PremierTM mass spectrometerData processing: OPLS-DA was carried out on the XCMS extracted intensities using SIMCA P+ v13 and Matlab.Lipids annotation was derived by searching m/z against online databases (METLIN, Lipidmaps and HMDB). <h3>Results</h3> Multivariate analyses between healthy and CD patients were performed to characterise lipid profile differences.Significant separation was observed in both serum and faeces between the two groups (Figure 1). Lipid metabolism is affected in CD patients compared to healthy controls. Correlation analysis showed that several triglyceride (TG) species were significantly associated with CD. TGs with medium to long chain fatty acid length and with saturations were identified at increased levels in CD patients (Figure 2). TGs with saturated fatty acids were prominent in faeces compare to serum. Moreover, TGs found in faeces were in higher concentration than in serum. <h3>Conclusion</h3> The metabonomic study showed profound variations in both serum and faeces of CD patients. These results highlight the association between the gut microbiota and mucosal barrier function which has downstream effect on lipid metabolism and inflammation in IBD. This metabonomic approach offers potential application in diagnosing CD. <h3>Disclosure of Interest</h3> None Declared
Gamma Delta T Cells (GDTCs) to Eliminate Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia (CML) : A Pre-Clinical Model
Authors: Gabrielle Melanie Siegers, Bassim Malas Al-Beirouti, Alister Mark Mathieson, Tania Cristina Felizardo, Simone Helke, Jeffrey A. Medin, Armand Keating
Journal: Blood (2008)
Second Stem Cell Harvest from Unrelated Donors for Patients with Relapse or Graft Failure after First Transplantation: Patient Age &gt;50 Years and Relapse of Malignant Disease Are Associated with Poor Outcome.
Authors: Uwe Platzbecker, Susanne Zapf, Cathrin Theuser, Alexander Schmidt, Claudia Rutt, Gerhard Ehninger, Martin Bornhauser
Journal: Blood (2006)
Association Between Intensity of Statin Therapy and Mortality in Patients With Atherosclerotic Cardiovascular Disease
Authors: Fatima Rodriguez, David J. Maron, Joshua W. Knowles, Salim S. Virani, Shoutzu Lin, Paul A. Heidenreich
Journal: JAMA Cardiology (2016)

High-intensity statin therapy is recommended for the secondary prevention of atherosclerotic cardiovascular disease (ASCVD). Nevertheless, statin therapy in general, and high-intensity statin therapy in particular, is underused in patients with established ASCVD.To determine the association between all-cause mortality and intensity of statin therapy in the Veterans Affairs health care system.A retrospective cohort analysis was conducted of patients aged 21 to 84 years with ASCVD treated in the Veterans Affairs health care system from April 1, 2013, to April 1, 2014. Patients who were included had 1 or more International Classification of Diseases, Ninth Revision codes for ASCVD on 2 or more different dates in the prior 2 years.Intensity of statin therapy was defined by the 2013 American College of Cardiology/American Heart Association guidelines, and use was defined as a filled prescription in the prior 6 months. Patients were excluded if they were taking a higher statin dose in the prior 5 years.The primary outcome was death from all causes adjusted for the propensity to receive high-intensity statins.The study sample included 509 766 eligible adults with ASCVD at baseline (mean [SD] age, 68.5 [8.8] years; 499 598 men and 10 168 women), including 150 928 (29.6%) receiving high-intensity statin therapy, 232 293 (45.6%) receiving moderate-intensity statin therapy, 33 920 (6.7%) receiving low-intensity statin therapy, and 92 625 (18.2%) receiving no statins. During a mean follow-up of 492 days, there was a graded association between intensity of statin therapy and mortality, with 1-year mortality rates of 4.0% (5103 of 126 139) for those receiving high-intensity statin therapy, 4.8% (9703 of 200 709) for those receiving moderate-intensity statin therapy, 5.7% (1632 of 28 765) for those receiving low-intensity statin therapy, and 6.6% (4868 of 73 728) for those receiving no statin (P < .001). After adjusting for the propensity to receive high-intensity statins, the hazard ratio for mortality was 0.91 (95% CI, 0.88-0.93) for those receiving high- vs moderate-intensity statins. The magnitude of benefit of high- vs moderate-intensity statins was similar, for an incident cohort hazard ratio of 0.93 (95% CI, 0.85-1.01). For patients aged 76 to 84 years, the hazard ratio was 0.91 (95% CI, 0.87-0.95). Patients treated with maximal doses of high-intensity statins had lower mortality (hazard ratio, 0.90; 95% CI, 0.87-0.94) compared with those receiving submaximal doses.We found a graded association between intensity of statin therapy and mortality in a national sample of patients with ASCVD. High-intensity statins were associated with a small but significant survival advantage compared with moderate-intensity statins, even among older adults. Maximal doses of high-intensity statins were associated with a further survival benefit.
Multiple organ-specific autoantibodies in patients with phenotypic type 2 diabetes in China: a post-hoc analysis of the China National Diabetes and Metabolic Disorders Study
Authors: Yufei Xiang, Gan Huang, Linong Ji, Weiping Jia, Jianping Weng, Juming Lu, Yaxi Zhu, Qiong Feng, Xia Li, Tubao Yang, Zhenqi Liu, Zhongyan Shan, Jie Liu, Haoming Tian, Qiuhe Ji, Dalong Zhu, Jiapu Ge, Lixiang Lin, Li Chen, Xiaohui Guo, Zhigang Zhao, Qiang Li, Xuan Zuo, Xinyuan Liu, Wenying Yang, Zhiguang Zhou
Journal: The Lancet Diabetes & Endocrinology (2016)
Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL)
Authors: David T Teachey, Simon F. Lacey, Pamela A Shaw, J Joseph Melenhorst, Noelle V. Frey, Shannon L Maude, David M. Barrett, Richard Aplenc, Fang Chen, Julie Fitzgerald, Vanessa Gonzalez, Edward Pequignot, Susan R. Rheingold, Scott Weiss, Jason C. White, Carl H. June, David L. Porter, Stephan A. Grupp
Journal: Blood (2015)
Safety and Efficacy of Venous Thromboembolism Prophylaxis with Low Molecular Weight Heparin in Hospitalised Patients with Acute Medical Illness and Renal Failure.
Authors: Enrico Tincani, Caterina Mannucci, Barbara Casolari, Fabrizio Turrini, Mark A. Crowther, Patrizia Ferrari, Anna Maria Cenci, Marco Bondi
Journal: Blood (2004)
BMP and WNT-Directed Transcription Factors TCF7L2/TCF4 and SMAD1 Bind to Distinct Hematopoietic-Specific Target Genes Depending on Cell Lineage
Authors: Eirini Trompouki, Teresa V. Bowman, Lee N Lawton, Zi Peng Fan, Anthony DiBiase, Jennifer Cech, Anna Sessa, Jocelyn LeBlanc, Pulin Li, Garrett Heffner, George Q. Daley, Richard Young, Leonard I. Zon
Journal: Blood (2010)
Acquisition of New In Vivo Genomic Change over Time in Multiple Myeloma.
Authors: Yu-Tzu Tai, Leutz Buon, Benjamin King, Cheng Li Cheng Li, Peter Burger Peter Burger, Xian-Feng Li, Weihua Song, Robert Schlossman, Paul Richardson, Kenneth C. Anderson, Nikhil Munshi
Journal: Blood (2007)
Superior Outcomes With Bortezomib Or Thalidomide Incorporated Into Autologous Stem Cell Transplantation (ASCT) Versus Novel Agent-Based Treatments For Elderly Patients With Newly Diagnosed Multiple Myeloma (MM): A Case-Match Comparison
Authors: Sara Bringhen, Lucia Pantani, Annalisa Pezzi, Beatrice Anna Zannetti, Paola Tacchetti, Patrizia Tosi, Alessandra Larocca, Katia Mancuso, Francesca Patriarca, Serena Rocchi, Nicoletta Testoni, Vittorio Montefusco, Barbara Gamberi, Annamaria Brioli, Giulia Marzocchi, Carolina Terragna, Antonio Palumbo, Michele Cavo
Journal: Blood (2013)
THU0071 Time To Remission in Early Rheumatoid Arthritis Is Shorter in Early Arthritis Clinic Compared To Mixed Outpatient Clinic
Authors: T.H. Hansen, K.M. Carlsen, P. Johansen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Early diagnosis of rheumatoid arthritis (RA) is of paramount importance as early effective treatment reduces long-term morbidity and mortality (1,2). Evidence suggests that simple clinical criteria, facilitates earlier referral of patients with suspected RA from general practitioners (GP9s) to the rheumatologist (3). <h3>Objectives</h3> Our hypothesis: Supplementary education of GP9s to identify RA and refer to an Early Arthritis Clinic (EAC) shortens time to remission compared to referral to a mixed outpatient clinic. <h3>Methods</h3> In July 2011, an EAC was established in Holbæk Hospital. GP9s in the hospitals catchment area were informed of the clinic, educated in the referral criteria and encouraged to refer patients suffering unspecific arthritis symptoms at early disease stages. A standardised referral form was contrived to simplify the referral process. Patients referred and diagnosed with RA were followed until remission. Patients in the trial were enrolled from July 2011 to April 2015. Controls were patients referred prior to the establishment of the EAC. The main outcome parameter was time from referral to low DAS28 &lt;3.2 or remission at DAS28 &lt;2.6. All patients were registered in the mandatory nationwide database DANBIO (4). Patients were evaluated and monitored by rheumatologists or rheumatology specialist nurses in the DANBIO at regular intervals and DAS28 was calculated at each visit. A Kaplan-Meier plot was calculated and compared using the log-rank test. The two groups were compared using the X2-test. <h3>Results</h3> As shown in the table, the two groups, EAC vs. controls, were similar in gender distribution. A relatively large proportion in each group already appeared to be in remission at the entry point, up to 16%, probably reflecting the proportion with only slight or minor disease activity. There was a significant proportion in the EAC that achieved both DAS28&lt;3.2 and DAS28&lt;2.6 compared to the control group. Likewise, a conspicuous difference was observed among the patients never achieving remission. The two Kaplan-Meier plots show the timely difference was highly significant indicating that time of remission was achieved very early. <h3>Conclusions</h3> Establishing an early arthritis clinic and supplementary RA education of GP9s shortens time to early disease activity or remission in patients with RA. <h3>References</h3> Lard LR, Visser H, Speyer I, vander Horst-Bruisma IE, Zwinderman AH, Breedveld FC et. al. Am J Med 2001;111(6):446–51. Nell, VP, Machold KP, Ererl G, Stamm TA, Uffmann M, Smolen JS. Rheumatology (Oxford) 2004;43(7):906–14 Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Ann Rheum Dis 2002;61(4):290–97. Danish Rheumatology Database. https://danbio-online.dk 2010 <h3>Acknowledgement</h3> Abbvie has supported this study with an unrestricted grant <h3>Disclosure of Interest</h3> None declared
Reciprocal Interaction Between Osteoclasts and T Cells: Osteoclasts Inhibit T Cell Proliferation by IDO Produced in Response to T Cell-Derived IFN-γ and CD40 Ligand
Authors: Haiyan Li, Yong Lu, Sungyoul Hong, Jianfei Qian, Zhiqiang Liu, Yuhuan Zheng, Yongsheng Lan, Jin He, Jing Yang, Qing Yi
Journal: Blood (2011)
Compromised Nuclear Sirtuins Activity Sensitizes BRCA-Proficient multiple Myeloma Cells to DNA Damage Agents
Authors: Michele Cea, Antonia Cagnetta, Aditya Munshi, Yu-Tzu Tai, Teru Hideshima, Dharminder Chauhan, Franco Patrone, Marco Gobbi, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2012)
Combination therapy with doxorubicin-loaded galactosylated poly(ethyleneglycol)-lithocholic acid to suppress the tumor growth in an orthotopic mouse model of liver cancer
Authors: Bijay Singh, Yoonjeong Jang, Sushila Maharjan, Hyeon-Jeong Kim, Ah Young Lee, Sanghwa Kim, Nomundelger Gankhuyag, Myeon-Sik Yang, Yun-Jaie Choi, Myung-Haing Cho, Chong-Su Cho
Journal: Biomaterials (2016)
High Levels of Soluble P-Selectin Are Associated with the Risk of Venous Thromboembolism and the P-Selectin Thr715 Variant.
Authors: Cihan Ay, Lea V. Jungbauer, Thomas Sailer, Theres Tengler, Silvia Koder, Alexandra Kaider, Simon Panzer, Peter Quehenberger, Christine Mannhalter, Ingrid Pabinger
Journal: Blood (2006)
PWE-042 Incidence and Risk Factors of Post Liver Transplant Colorectal Malignancy in PSC: Abstract PWE-042 Table 1
Authors: VM Sagar, PJ Trivedi, G Aidoo-Micah, BK Gunson, G Hirschfield
Journal: Gut (2016)

<h3>Introduction</h3> Patients with primary sclerosing cholangitis (PSC) and co-existing colonic inflammatory bowel disease (IBD) have an increased lifetime risk of developing colorectal cancer (CRC); a risk that persists after liver transplantation. Aim: Assess the incidence rate (I.R.) of colonic dysplasia and/or cancer in patients transplanted for PSC, and determine any factors specific to post-transplant care associated with an increased CRC risk. <h3>Methods</h3> The cohort included all patients transplanted from 1987 to 2015 for PSC with concomitant colitis. Time zero was set as the point of first liver transplant. The study end-point was the time to first dysplasia or any higher lesion. Patients were censored at time of colectomy (for a non-CRC indication), death or last date of CRC-free follow up. Statistical methods employed for determining potential risk factors included Cox-proportional hazards and Kaplan-Meier estimates. <h3>Results</h3> Overall, 306 patients were transplanted during this time period. 202 patients (66%) had underlying IBD and of this group 191 patients (95%) had co-existing colitis. The final study population was 163 patients who had colitis with an intact colon. The I.R. of developing colonic dysplasia or higher lesions was 18.9 cases per 1,000 patient years and of colonic high grade dysplasia (HGD) or neoplasia was 10.4 cases per 1,000 patient years. There has been an increase in incidence rates by year of transplant (Table 1). No risk factors for the development of colonic dysplasia or above post liver transplantation were statistically significant. These risk factors included the number of colitis flares (&gt;0, &gt;1, &gt;2), the use of cyclosporine (versus tacrolimus), the use of azathioprine (versus mycophenolate mofetil), thiopurine use, use of ursodeoxycholic acid, advancing age and male gender. <h3>Conclusion</h3> The incidence of colonic dysplasia in the PSC post-transplant population is rising. Further review of specific colitis findings need to be evaluated in order to aid in any potential risk factors for CRC development. <h3>Disclosure of Interest</h3> None Declared
AB0948 Signal Peptide-Cub-Egf Domain-Containing Protein (SCUBE); A Novel Marker in Relation with Anjiogenesis in Rheumatoid Arthritis?
Authors: E. Capkin, M. Arslan, A. Mentese, M. Karkucak, S. Özer Yaman, N. Cilesizoglu, D. Altay
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid Arthritis (RA) is a multifactorial, systemic, progressive, inflammatory disease which is characterized with bone and cartilage destruction. Synovial angiogenesis is important at the etiopathology. Recently with the better understanding of RA pathogenesis, the target specific treatment approaches come up with better results. <h3>Objectives</h3> The purpose is to study levels of newly identified plasma signal peptide-CUP-EGF domain containing protein (SCUBE) 1and 3 in RA patients. Moreover, to determine whether there exists any correlation between these proteins, other angiogenesis parameters and disease activities <h3>Methods</h3> This study covers 106 patients diagnosed with RA associated with 2010 American Collage of Rheumatology (ACR) diagnosis criteria matched with healthy controllers who are equivalent of RA patients in terms of age and gender. All necessary data such as age, gender and body mass index of all participants were recorded. Detailed background information and examination of the patients are recorded and disease activity scores (DAS28) were figured out. The levels of SCUBE 1–3, Vascular Endotedial Growth Factor (VEGF), Matrix metaloproteinaz-9 (MM-9), Interlökin-6 (IL-6), CD40L are evaluated with the method of Enzyme-Linked Immuno-Sorbent Assay (ELISA) in both patients and control group <h3>Results</h3> This study covers 201 individuals 106 of whom were diagnosed with RA (82 women, 24 men) and 95 of them were healthy controllers (64 women, 31 men). Age, body mass index (BMI) and gender distribution of both groups were very similar to one another. Significant differences were observed between RA patients and healthy controller groups in terms of SCUBE 1 (respectively1.28±1.41ng/mL, 0.94±0.67ng/mL p=0.002) and CD40L MMP-9 levels (p&lt;0.001, p=0.012). Any significant difference was not detected between disease activity and SCUBE 1–3 and other angiogenesis markers. Any significant correlation was not determined between disease activities, SCUBE 1–3 and other parameters. <h3>Conclusions</h3> Levels of SCUBE might be considered as a significant marker in the disease pathogenesis independent from other parameters in the RA diagnosed patients. <h3>References</h3> Szekanecz Z, Besenyei T, Paragh G, Koch AE Angiogenesis in rheumatoid arthritis.Autoimmunity. 2009;7:563–731 Lainer-Carr D, Brahn E. Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol. 2007;3:434–42. Yang R-B, Ng CKD, Wasserman SM, et al. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J Biol Chem 2002;277:464–73. Yanga M, Mingyang G, Yonghe H Jiang y. Scube regulates synovial angiogenesis-related signaling. Medical Hypotheses 2013;27: 948–953 <h3>Disclosure of Interest</h3> None declared
Marked Activity of Bortezomib, Rituximab, and Dexamethason in Relapsed and Refractory Mantle Cell Lymphoma.
Authors: Johannes Drach, Hannes Kaufmann, Oskar Pichelmayer, Verena Sagaster, Sonja Seidl, Andreas Chott, Christoph Zielinski, Markus Raderer
Journal: Blood (2006)
Immunohistochemical Analyses for Potential Biomarkers of Bortezomib Activity in Mantle Cell Lymphoma from the PINNACLE Phase 2 Trial.
Authors: Andre Goy, Steven H. Bernstein, Alice McDonald, Michael D. Pickard, Mark D. Fleming, Barb Bryant, William Trepicchio, Richard I. Fisher, Anthony Boral, George Mulligan
Journal: Blood (2007)
Variation of Sorcin’s Expression in the Reversion of Multidrug Resistance of K562/A02 Leukemic Line with Tetrandrine.
Authors: Bao-An Chen Chen, Jing Li, Jia-Hua Ding, Chong Gao, Yun-Yu Sun, Feng Gao, Jun Wang, Gang Zhao, Ning-Na Chen, Jian Chen, Xiao-Ping Pei
Journal: Blood (2007)
Mechanisms of Telomere Maintenance Dysfunction in B-Chronic Lymphocytic Leukemia Through CpG Island Methylation
Authors: Morgan Auchter, Sandrine Medves, Laetitia Chambeau, Sophie Gazzo, Etienne Moussay, Wim Ammerlaan, Hamid Morjani, Vincent Géli, Valérie Palissot, Guy J. Berchem, Gilles Salles, Thomas Wenner
Journal: Blood (2012)
Outcome with Hyper-CVAD/MTX-Ara-C, a Dose-Intensive Regimen, in Acute Lymphocytic Leukemia and Highly Aggressive Lymphoma in China.
Authors: Ting Niu, Ting Liu, Bing Xiang, Hong Chang, Yong-qian Jia, Huan-ling Zhu
Journal: Blood (2007)
PTH-025 Endoscopic Retrograde Cholangiopancreatography (ERCP): A Point Prevalence Study of Hospitals in England
Authors: J Morgan, T Wardle
Journal: Gut (2016)

<h3>Introduction</h3> While ERCP is a common therapeutic procedure, to date no studies have ever been conducted which examine its availability, the types of technique or nature of training. This is a prospective study which uses descriptive data from NHS hospitals in England. <h3>Methods</h3> Between February and August 2015 a questionnaire was sent to consultants who perform ERCP. Further information was obtained from support staff by telephone, email or freedom of information request. The questions concerned the number of dedicated ERCP lists, personnel performing ERCP, the techniques used, the type of anaesthesia or sedation available, opportunities for trainees and availability of dedicated training lists. <h3>Results</h3> 146 trusts were contacted and 126 consultants responded. These consultants provided ERCP services for 170 hospitals. Not all questions were answered. Hospitals: 139 hospitals (82%) offered ERCP services of between 1 and 10 lists per week (mean 2.8, mode 2), though 1 hospital did not have a dedicated list. All 31 hospitals that did not offer ERCP (18%) did have access via a neighbouring hospital, usually within the same trust. Practitioners: Of the 373 practitioners who performed ERCP, 316 (85%) were physicians, 46 (12%) surgeons, 7 (1%) radiologists, 1 nurse and 3 unspecified. The number of practitioners per hospital ranged between 1 and 7, though most hospitals had 2. Trainees: Of the 139 hospitals performing ERCP, 69 (50%) had trainees, but only 33 (48%) of these had dedicated training lists. Techniques: Most hospitals (121/136; 89%) use short wire technique, while 69 (51%) use long wire and 54 (40%) use both. 110 hospitals practice post sphincterotomy balloon sphincteroplasty (81%). Sedation: Propofol sedation was available for ERCP in only 46/136 (34%) hospitals and general anaesthetic was available in only 70 (51%) hospitals. 90/136 (66%) hospitals had no access to propofol and 66/136 (49%) hospitals had no access to a general anaesthetic list. <h3>Conclusion</h3> This point prevalence study has shown that ERCP is widely available in England. Physicians perform the majority of ERCPs. Only 69 hospitals (50%) were training practitioners. Although relatively new, both short wire technique and post sphincterotomy balloon sphincteroplasty are commonly used. Only a quarter of hospitals had propofol lists for ERCP, despite guidance from the British Society of Gastroenterology and the Royal College of Anaesthetists 2011.<sup>1,2</sup> <h3>References</h3> 1 http://www.bsg.org.uk/images/stories/docs/clinical/guidance/rcoa_bsg_propofol_11.pdf 2 http://www.bsg.org.uk/sections/bsg-endoscopy-articles/propofol-for-ercp-an-update.html <h3>Disclosure of Interest</h3> None Declared
Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism
Authors: Akihiko S Kato, Kevin D Burris, Kevin M Gardinier, Douglas L Gernert, Warren J Porter, Jon Reel, Chunjin Ding, Yuan Tu, Douglas A Schober, Matthew R Lee, Beverly A Heinz, Thomas E Fitch, Scott D Gleason, John T Catlow, Hong Yu, Stephen M Fitzjohn, Francesca Pasqui, He Wang, Yuewei Qian, Emanuele Sher, Ruud Zwart, Keith A Wafford, Kurt Rasmussen, Paul L Ornstein, John T R Isaac, Eric S Nisenbaum, David S Bredt, Jeffrey M Witkin
Journal: Nature Medicine (2016)
Immunophenotypic Analysis of Myeloma Precursors: Antigens for Therapeutic Targeting
Authors: Martin Perez-Andres, Bruno Paiva, Leandro Thiago, Nico A Bos, Dirk Hose, Bernard Klein, Surinder S Sahota, Pieter Sonneveld, Karin Vanderkerken, Niklas Zojer, Hans Erik Johnsen, Jesus F San Miguel, Alberto Orfao
Journal: Blood (2010)
Improved Modifications Of Nitric Oxide Donating Aspirin (NO-ASA): Getting a Grip On TP53 Mutated High-Risk Chronic Lymphocytic Leukemia (CLL)
Authors: Sylvia Krallman, Simon Jonas Poll-Wolbeck, Hanna Flamme, Mark Krueger, Albrecht Berkessel, Michael Hallek, Karl-Anton Kreuzer, Dr. med.
Journal: Blood (2013)